Web Desc
Emerging Cell Therapies: Realizing the Vision of NextGen Cell Therapeutics - VIRTUAL CONTENT AVAILABLE ON DEMAND
Organizer(s): Kole T. Roybal, Alex Marson and Yvonne Y. Chen
Date: January 25 - 27, 2021
Location: Virtual at your computer. Recorded presentation content is available On Demand.
Sponsored by AstraZeneca, BioLegend, Inc., BlueRock Therapeutics, Nektar Therapeutics, Novo Nordisk A/S and TCR² Therapeutics
For important information on the coronavirus, please click here
Summary of Meeting:
Cellular therapeutics are poised to be a next pillar of medicine along with small molecules and biologics. These living drugs have a unique capacity for more complex decision-making and therapeutic responses, potentially alleviating the need for chronic treatment. Next-generation cell therapies will need to adapt and respond to disease progression, essentially functioning as microscopic “physicians” capable of sensing, diagnosing, and eradicating disease via multifaceted mechanisms that are difficult to resist yet similar to our natural immune system. Advances in engineered T cell therapeutics are being FDA approved and are now transforming treatment plans for cancers that previously had few therapeutic options. While there have been unprecedented complete responses in a subset of hematological malignancies, the current therapies can show significant toxicity and on the other hand show a lack of efficacy in solid tumors. Beyond cancer, engineered cell therapies could have significant impact in the treatment of autoimmunity, metabolic disorders and in regenerative medicine. This conference will therefore cover next-generation cellular engineering approaches designed to tackle refractory diseases such as solid tumors, while also addressing the higher safety requirements for diseases beyond late-stage metastatic cancers. This conference brings together clinically minded cell therapists, synthetic biologists, genome and protein engineers, systems biologists, and immunologists; this combined expertise is essential to establish cells as a safe and effective therapeutic strategy across a range of diseases. Smart cellular therapeutics of the future must be easily customizable, have intrinsic control systems to prevent toxicity, and be able to overcome rapidly evolving mechanisms preventing disease resolution; this conference aims to address these topics by convening global experts across a range of relevant disciplines.
Scholarship Deadline: November 1 2020
Abstract Deadline: December 15 2020
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
AstraZenecaBioLegend, Inc.BlueRock TherapeuticsNektar TherapeuticsNovo Nordisk A/STCR² TherapeuticsThermo Fisher Scientific Inc.
We gratefully acknowledge additional support for this conference from:
AdipoGen Life SciencesAmerican Association for Cancer Research (AACR)DCVC BioNanoString Technologies, Inc.
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1R13CA254054-01
Funding for this conference was made possible (in part) by 1R13CA254054-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Monday, January 25 | 8:00AM - 8:40AM
Welcoming Remarks and Keynote Address (8am Denver/Mountain T
ime Start)

Speaker 1 of 2
* Kole T. Roybal, University of California, San Francisco, USA

Monday, January 25 | 8:00AM - 8:40AM
Welcoming Remarks and Keynote Address (8am Denver/Mountain T
ime Start)

Speaker 2 of 2
David Baker, University of Washington, USA
Computational Protein Design for Next-Generation Cellular Therapeutics

Monday, January 25 | 8:40AM - 11:00AM
The Current State of Cellular Therapies for Cancer: Lessons
from the Clinic (8:40am Denver/Mountain Time Start)


Speaker 1 of 7
* Kole T. Roybal, University of California, San Francisco, USA

Monday, January 25 | 8:40AM - 11:00AM
The Current State of Cellular Therapies for Cancer: Lessons
from the Clinic (8:40am Denver/Mountain Time Start)


Speaker 2 of 7
* Yvonne Y. Chen, University of California, Los Angeles, USA

Monday, January 25 | 8:40AM - 11:00AM
The Current State of Cellular Therapies for Cancer: Lessons
from the Clinic (8:40am Denver/Mountain Time Start)


Speaker 3 of 7
David Edward Gilham, Celyad, Belgium
Next-Generation CART Approaches Exploiting Natural Killer Receptor Targeting

Monday, January 25 | 8:40AM - 11:00AM
The Current State of Cellular Therapies for Cancer: Lessons
from the Clinic (8:40am Denver/Mountain Time Start)


Speaker 4 of 7
Marcela V. Maus, Harvard Medical School, USA
[NOT AVAILABLE ON DEMAND] New T Cell Therapeutics

Monday, January 25 | 8:40AM - 11:00AM
The Current State of Cellular Therapies for Cancer: Lessons
from the Clinic (8:40am Denver/Mountain Time Start)


Speaker 5 of 7
Christine E. Brown, Beckman Research Institute, City of Hope, USA
CAR T Cells for the Treatment of Brain Malignancies

Monday, January 25 | 8:40AM - 11:00AM
The Current State of Cellular Therapies for Cancer: Lessons
from the Clinic (8:40am Denver/Mountain Time Start)


Speaker 6 of 7
Isabelle Riviere, Memorial Sloan-Kettering Cancer Center, USA
Manufacturing Next-Generation Cellular Therapies

Monday, January 25 | 8:40AM - 11:00AM
The Current State of Cellular Therapies for Cancer: Lessons
from the Clinic (8:40am Denver/Mountain Time Start)


Speaker 7 of 7
Barbra Sasu, Allogene Therapeutics, USA
Allogeneic CAR T Therapy for the Treatment of Cancer

Monday, January 25 | 12:30PM - 1:30PM
Career Roundtable (12:30pm Denver/Mountain Time Start)

Speaker 1 of 3
Darrell J. Irvine, Massachusetts Institute of Technology, USA

Monday, January 25 | 12:30PM - 1:30PM
Career Roundtable (12:30pm Denver/Mountain Time Start)

Speaker 2 of 3
Marcela V. Maus, Harvard Medical School, USA

Monday, January 25 | 12:30PM - 1:30PM
Career Roundtable (12:30pm Denver/Mountain Time Start)

Speaker 3 of 3
Jane L. Grogan, Arsenal Biosciences, USA

Monday, January 25 | 1:30PM - 3:00PM
Poster Session 1 (1:30pm Denver/Mountain Time Start)


Monday, January 25 | 3:00PM - 6:00PM
New Approaches for Programming Cellular Therapeutics (3pm De
nver/Mountain Time Start)


Speaker 1 of 9
* Alex Marson, University of California, San Francisco, USA
Reprogramming Immune Cell Therapeutics with Non-Viral Gene Editing Approaches

Monday, January 25 | 3:00PM - 6:00PM
New Approaches for Programming Cellular Therapeutics (3pm De
nver/Mountain Time Start)


Speaker 2 of 9
Aaron Ring, Yale School of Medicine, USA
Engineered Cytokines for Cancer Immunotherapy

Monday, January 25 | 3:00PM - 6:00PM
New Approaches for Programming Cellular Therapeutics (3pm De
nver/Mountain Time Start)


Speaker 3 of 9
Dario Campana, National University of Singapore, Singapore
Expanding the Functional Capacity of Therapeutic Immune Cells

Monday, January 25 | 3:00PM - 6:00PM
New Approaches for Programming Cellular Therapeutics (3pm De
nver/Mountain Time Start)


Speaker 4 of 9
* Ahmad S. Khalil, Boston University, USA
Design of Eukaryotic Gene Regulatory Circuits

Monday, January 25 | 3:00PM - 6:00PM
New Approaches for Programming Cellular Therapeutics (3pm De
nver/Mountain Time Start)


Speaker 5 of 9
Romina Marone, University of Basel, DBM, Switzerland
Short Talk: Elimination of Mouse B Cells by Non-Virally Engineered CAR19 Knock-In T Cells

Monday, January 25 | 3:00PM - 6:00PM
New Approaches for Programming Cellular Therapeutics (3pm De
nver/Mountain Time Start)


Speaker 6 of 9
Alessio David Nahmad, Tel Aviv University, Israel
Short Talk: Engineering B Cells in-vivo Elicits Potent Cellular and Serological Responses in Mice

Monday, January 25 | 3:00PM - 6:00PM
New Approaches for Programming Cellular Therapeutics (3pm De
nver/Mountain Time Start)


Speaker 7 of 9
Aditya Murthy, Genentech, Inc., USA
Short Talk: Efficient Gene Knockout in Primary Myeloid Cells by Non-Viral Delivery of CRISPR-Cas9

Monday, January 25 | 3:00PM - 6:00PM
New Approaches for Programming Cellular Therapeutics (3pm De
nver/Mountain Time Start)


Speaker 8 of 9
Jonathan B. Gilbert, SQZ Biotechnology, USA
Short Talk: Microfluidic Cell Squeezing Enables the Generation of Novel Cell Therapies for
Diverse Clinical Applications


Monday, January 25 | 3:00PM - 6:00PM
New Approaches for Programming Cellular Therapeutics (3pm De
nver/Mountain Time Start)


Speaker 9 of 9
Owen J. L. Rackham, Duke-NUS, Singapore
Short Talk: Using Data-Driven Approaches to Develop Engineered Cell Therapies

Tuesday, January 26 | 8:00AM - 11:00AM
Next-Generation Cellular Therapeutics for Cancer (8am Denve
r/Mountain Time Start)


Speaker 1 of 7
* Yvonne Y. Chen, University of California, Los Angeles, USA
[NOT AVAILABLE ON DEMAND] Enhancing T-Cell Therapies by Rational Biomolecular Engineering

Tuesday, January 26 | 8:00AM - 11:00AM
Next-Generation Cellular Therapeutics for Cancer (8am Denve
r/Mountain Time Start)


Speaker 2 of 7
Martin Pule, University College London, UK
T Cell Therapies with Engineered Control Systems

Tuesday, January 26 | 8:00AM - 11:00AM
Next-Generation Cellular Therapeutics for Cancer (8am Denve
r/Mountain Time Start)


Speaker 3 of 7
* Kole T. Roybal, University of California, San Francisco, USA
Control and Customization of Immune Cell Therapies for Cancer

Tuesday, January 26 | 8:00AM - 11:00AM
Next-Generation Cellular Therapeutics for Cancer (8am Denve
r/Mountain Time Start)


Speaker 4 of 7
Jane L. Grogan, Arsenal Biosciences, USA
Development of Next-Generation T Cell Therapies

Tuesday, January 26 | 8:00AM - 11:00AM
Next-Generation Cellular Therapeutics for Cancer (8am Denve
r/Mountain Time Start)


Speaker 5 of 7
Timothy K. Lu, Massachusetts Institute of Technology, USA
Synthetic Biology Tools to Stimulate Anti-Tumor Immunity

Tuesday, January 26 | 8:00AM - 11:00AM
Next-Generation Cellular Therapeutics for Cancer (8am Denve
r/Mountain Time Start)


Speaker 6 of 7
Christopher Bourne, Memorial Sloan Kettering Cancer Center, USA
Short Talk: Mechanisms of Adoptive T Cell Micropharmacies

Tuesday, January 26 | 8:00AM - 11:00AM
Next-Generation Cellular Therapeutics for Cancer (8am Denve
r/Mountain Time Start)


Speaker 7 of 7
Rogelio A. Hernandez-Lopez, University of California San Francisco, USA
Short Talk: T Cell Circuits that Sense Antigen Density with an Ultrasensitive Threshold

Tuesday, January 26 | 11:30AM - 12:30PM
Meet the Editors (11:30am Denver/Mountain Time Start)

Speaker 1 of 3
Zeljko Durdevic, EMBO Press, Germany

Tuesday, January 26 | 11:30AM - 12:30PM
Meet the Editors (11:30am Denver/Mountain Time Start)

Speaker 2 of 3
Sara Hamilton, Cell Press, USA

Tuesday, January 26 | 11:30AM - 12:30PM
Meet the Editors (11:30am Denver/Mountain Time Start)

Speaker 3 of 3
Claudia G. Willmes, Cell Press, USA

Tuesday, January 26 | 3:00PM - 6:00PM
Beyond Effector T Cell Therapeutics (3pm Denver/Mountain Tim
e Start)


Speaker 1 of 6
* Saar I. Gill, University of Pennsylvania, USA
Engineered Macrophage Therapeutics

Tuesday, January 26 | 3:00PM - 6:00PM
Beyond Effector T Cell Therapeutics (3pm Denver/Mountain Tim
e Start)


Speaker 2 of 6
Dan S. Kaufman, University of California, San Diego, USA
NK Cell Therapies for Cancer

Tuesday, January 26 | 3:00PM - 6:00PM
Beyond Effector T Cell Therapeutics (3pm Denver/Mountain Tim
e Start)


Speaker 3 of 6
Tal Danino, Columbia University, USA
Programming Bacteria as a Cancer Therapy

Tuesday, January 26 | 3:00PM - 6:00PM
Beyond Effector T Cell Therapeutics (3pm Denver/Mountain Tim
e Start)


Speaker 4 of 6
* Megan K. Levings, University of British Columbia, Canada
NextGen Treg Therapies

Tuesday, January 26 | 3:00PM - 6:00PM
Beyond Effector T Cell Therapeutics (3pm Denver/Mountain Tim
e Start)


Speaker 5 of 6
Tara L. Deans, University of Utah, USA
Synthetic Biology Tools for the Development of Engineered Stem Cell Therapeutics

Tuesday, January 26 | 3:00PM - 6:00PM
Beyond Effector T Cell Therapeutics (3pm Denver/Mountain Tim
e Start)


Speaker 6 of 6
Tyler Hill, University of Washington, USA
Short Talk: Engraftment of Gene-Engineered Human Plasma Cells in Humanized Mice Shows Early Promise for the Feasibility of Novel Plasma Cell-Based Therapies

Wednesday, January 27 | 8:00AM - 11:00AM
Engineering Materials for Cellular Therapeutics (8am Denver/
Mountain Time Start)


Speaker 1 of 8
Matthias Stephan, Fred Hutchinson Cancer Research Center, USA
Synthetic mRNA Nanocarriers for the in situ Programming of Disease-Specific Immune Cells

Wednesday, January 27 | 8:00AM - 11:00AM
Engineering Materials for Cellular Therapeutics (8am Denver/
Mountain Time Start)


Speaker 2 of 8
* Darrell J. Irvine, Massachusetts Institute of Technology, USA
Endogenous Immunity Primed by Vaccine-Boosted CAR T Cell Therapy

Wednesday, January 27 | 8:00AM - 11:00AM
Engineering Materials for Cellular Therapeutics (8am Denver/
Mountain Time Start)


Speaker 3 of 8
* Tatiana Segura, Duke University, USA
Biomaterials for Tissue Repair and Regulation of Inflammation

Wednesday, January 27 | 8:00AM - 11:00AM
Engineering Materials for Cellular Therapeutics (8am Denver/
Mountain Time Start)


Speaker 4 of 8
David J. Mooney, Harvard University, USA
Artificial APCs to Manufacture and Boost T Cell Therapies

Wednesday, January 27 | 8:00AM - 11:00AM
Engineering Materials for Cellular Therapeutics (8am Denver/
Mountain Time Start)


Speaker 5 of 8
Andy Tay, National University of Singapore, Singapore
Short Talk: High-Aspect Ratio Nano-Structures for Efficient, Minimally Perturbative and Transgene-Free Immuno-Transfection

Wednesday, January 27 | 8:00AM - 11:00AM
Engineering Materials for Cellular Therapeutics (8am Denver/
Mountain Time Start)


Speaker 6 of 8
Jesus Paez Mayorga, Houston Methodist Hospital, USA
Short Talk: Implantable Cell Therapy Platform With In Situ Pre-Vascularization and Localized Immunosuppression for Allogeneic Cell Transplantation

Wednesday, January 27 | 8:00AM - 11:00AM
Engineering Materials for Cellular Therapeutics (8am Denver/
Mountain Time Start)


Speaker 7 of 8
Gloria Delfanti, San Raffaele Scientific Institute, Italy
Short Talk: Dual Targeting of Cancer and Suppressive Myeloid Cells by Tumor-Redirected iNKT Cells and Antigen-Carrying Microparticles

Wednesday, January 27 | 8:00AM - 11:00AM
Engineering Materials for Cellular Therapeutics (8am Denver/
Mountain Time Start)


Speaker 8 of 8
Sailan Shui, École polytechnique fédérale de Lausanne, Switzerland
Short Talk: Generalizable Computational Approach to Design Chemically Controlled Protein Switches with Multi-Logics for Cell-Based Therapeutics

Wednesday, January 27 | 1:00PM - 3:00PM
Networking Lounge (1pm Denver/Mountain Time Start)


Wednesday, January 27 | 3:00PM - 5:45PM
Immune Cell Biology: Implications for Cellular Immunotherapy
(3pm Denver/Mountain Time Start)


Speaker 1 of 7
* Miriam Merad, Mount Sinai School of Medicine, USA
Myeloid Cell Contribution to Tumor Lesion Composition and Outcome

Wednesday, January 27 | 3:00PM - 5:45PM
Immune Cell Biology: Implications for Cellular Immunotherapy
(3pm Denver/Mountain Time Start)


Speaker 2 of 7
* Andrea Schietinger, Memorial Sloan Kettering Cancer Center, USA
Regulation of T Cell Function in Tumors

Wednesday, January 27 | 3:00PM - 5:45PM
Immune Cell Biology: Implications for Cellular Immunotherapy
(3pm Denver/Mountain Time Start)


Speaker 3 of 7
Joseph C. Sun, Memorial Sloan Kettering Cancer Center, USA
NK Cells in Health and Disease

Wednesday, January 27 | 3:00PM - 5:45PM
Immune Cell Biology: Implications for Cellular Immunotherapy
(3pm Denver/Mountain Time Start)


Speaker 4 of 7
Debattama Sen, Massachusetts General Hospital, USA
Short Talk: Disrupting Enhancers within the Core Epigenetic Program of Exhaustion Improves CD8+ T Cell Responses and Enhances Tumor Control

Wednesday, January 27 | 3:00PM - 5:45PM
Immune Cell Biology: Implications for Cellular Immunotherapy
(3pm Denver/Mountain Time Start)


Speaker 5 of 7
Baris Avsaroglu, University of California, San Francisco, USA
Short Talk: Mapping Cellular Interactions between Cancer and Normal Cells via Synthetic Notch Ligand/Receptor Pairs

Wednesday, January 27 | 3:00PM - 5:45PM
Immune Cell Biology: Implications for Cellular Immunotherapy
(3pm Denver/Mountain Time Start)


Speaker 6 of 7
Micah Benson, KSQ Therapeutics, USA
Short Talk: Unbiased Design of Engineered T Cell Therapies Using Functional CRISPR/Cas9 Screens

Wednesday, January 27 | 3:00PM - 5:45PM
Immune Cell Biology: Implications for Cellular Immunotherapy
(3pm Denver/Mountain Time Start)


Speaker 7 of 7
Nayara Leite, Harvard University, USA
Short Talk: Uncovering the Cell-Type Specificity in Human T1D Immune Activation Using iPSC-ß Cells

Wednesday, January 27 | 5:45PM - 6:00PM
Closing Remarks (5:45pm Denver/Mountain Time Start)

Speaker 1 of 3
Kole T. Roybal, University of California, San Francisco, USA

Wednesday, January 27 | 5:45PM - 6:00PM
Closing Remarks (5:45pm Denver/Mountain Time Start)

Speaker 2 of 3
Yvonne Y. Chen, University of California, Los Angeles, USA

Wednesday, January 27 | 5:45PM - 6:00PM
Closing Remarks (5:45pm Denver/Mountain Time Start)

Speaker 3 of 3
Alex Marson, University of California, San Francisco, USA

*Session Chair.